Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

15.20
+0.22001.47%
Post-market: 15.19-0.0100-0.07%16:19 EDT
Volume:115.56K
Turnover:1.76M
Market Cap:1.95B
PE:-20.65
High:15.37
Open:15.11
Low:15.08
Close:14.98
52wk High:21.50
52wk Low:9.88
Shares:128.30M
Float Shares:78.65M
Volume Ratio:0.71
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7359
EPS(LYR):-0.8457
ROE:-18.22%
ROA:-6.16%
PB:3.39
PE(LYR):-17.97

Loading ...

Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy

Simply Wall St.
·
Apr 09

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

GlobeNewswire
·
Apr 08

Mesoblast's Duchenne Muscular Dystrophy Treatment Heads for US Registrational Clinical Trial; Shares Up Pre-Bell

MT Newswires Live
·
Apr 08

Mesoblast Wins FDA Nod for Registrational Ryoncil Trial in Duchenne Muscular Dystrophy

TIPRANKS
·
Apr 08

Mesoblast Ltd - FDA Clears Ryoncil Ind for Registration Trial in Dmd

THOMSON REUTERS
·
Apr 08

Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga_recent_news
·
Apr 07

Mesoblast Plans New Share Issue to Raise Capital

TIPRANKS
·
Apr 07

BRIEF-Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M

Reuters
·
Apr 07

Mesoblast reports March quarter Ryoncil sales of $30.3M

TIPRANKS
·
Apr 07

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

GlobeNewswire
·
Apr 07

Mesoblast Ltd - Ryoncil Net Revenue for Quarter Increases to US$30.3M

THOMSON REUTERS
·
Apr 07

Mesoblast Earnings Call: Ryoncil Momentum, Pipeline Upside

TIPRANKS
·
Mar 27

Mesoblast CEO Granted Additional Options Following Shareholder Approval

TIPRANKS
·
Mar 20

Mesoblast Issues 3.25 Million Unquoted Options Under Employee Incentive Scheme

TIPRANKS
·
Mar 20

Mesoblast Sets Inaugural R&D Day to Showcase Strategy, Ryoncil and Pipeline

TIPRANKS
·
Mar 18

Mesoblast Discloses Director Gregory George’s Share and ADS Purchases in Early March 2026

TIPRANKS
·
Mar 13

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

GlobeNewswire
·
Mar 12

Mesoblast hires Regeneron veteran to lead clinical development and medical affairs

TIPRANKS
·
Mar 12

Mesoblast Director Gregory George Deepens Stake with US$16.4m Share Purchases

TIPRANKS
·
Mar 10

Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys

MT Newswires Live
·
Mar 09